RBC Capital analyst Shagun Singh names Boston Scientific the firm’s top large-cap pick as part of a broader research note on MedTech previewing 2024. The firm also keeps its Outperform rating and $67 price target on the shares. The company should deliver at least high-single-digit revenue growth in 2024 and likely exceed those levels aided by PFA approval now in Q1, the analyst tells investors in a research note. The firm also notes that the company’s EP and Watchman franchises should remain strong growth drivers this year.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BSX:
- NeuroPace price target raised to $17 from $12 at Lake Street
- Axonics downgraded to Peer Perform from Outperform at Wolfe Research
- Unusually active option classes on open January 8th
- M & A News: Boston Scientific (NYSE:BSX) to Acquire Axonics in $3.7B Deal
- Axonics to be acquired by Boston Scientific for $71 per share
